AVDL VS INVA Stock Comparison

Performance

AVDL
100/100

AVDL returned 58.04% in the last 12 months. Based on SPY's performance of -21.06%, its performance is above average giving it a score of 100 of 100.

INVA
10/100

INVA returned 4.04% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

AVDL
80/100

5 analysts offer 12-month price targets for AVDL. Together, they have an average target of 10.67, the most optimistic target put AVDL at 12 within 12-months and the most pessimistic has AVDL at 9.

INVA
45/100

5 analysts offer 12-month price targets for INVA. Together, they have an average target of 13, the most optimistic target put INVA at 13 within 12-months and the most pessimistic has INVA at 13.

Sentiment

AVDL
70/100

AVDL had a bullish sentiment score of 70.23% across Twitter and StockTwits over the last 12 months. It had an average of 6.78 posts, 3.03 comments, and 4.97 likes per day.

INVA
73/100

INVA had a bullish sentiment score of 72.81% across Twitter and StockTwits over the last 12 months. It had an average of 1.48 posts, 0.17 comments, and 0.74 likes per day.

Technicals

AVDL
11/100

AVDL receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

INVA
89/100

INVA receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

Earnings

AVDL
10/100

AVDL has missed earnings 7 times in the last 20 quarters.

INVA
10/100

INVA has missed earnings 6 times in the last 20 quarters.

Profit

AVDL
10/100

Out of the last 20 quarters, AVDL has had 1 profitable quarters and has increased their profits year over year on 1 of them.

INVA
70/100

Out of the last 20 quarters, INVA has had 19 profitable quarters and has increased their profits year over year on 7 of them.

Volatility

AVDL
56/100

AVDL has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.

INVA
52/100

INVA has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Avadel Pharmaceuticals plc Ordinary Share Summary

Nasdaq / AVDL

Healthcare

Drug Manufacturers - Specialty & Generic

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Innoviva, Inc. Common Stock Summary

Nasdaq / INVA

Healthcare

Biotechnology

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Power up your portfolio